Research programme: antivirals - Biota/NIAID/USAMRIID
Latest Information Update: 29 May 2007
At a glance
- Originator Biota Holdings
- Developer Biota Holdings; National Institute of Allergy and Infectious Diseases; United States Army Medical Research Institute of Infectious Diseases
- Class
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Severe acute respiratory syndrome; Smallpox
Most Recent Events
- 20 Oct 2003 Preclinical trials in Severe acute respiratory syndrome in Australia (unspecified route)
- 20 Oct 2003 Preclinical trials in Severe acute respiratory syndrome in USA (unspecified route)
- 20 Oct 2003 Preclinical trials in Smallpox in Australia (unspecified route)